国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (3): 216-219.doi: 10.3760/cma.j.issn.1673422X.2016.03.015

• 综述 • 上一篇    下一篇

靶向药物和全脑放疗治疗非小细胞肺癌脑转移的研究现状

 王小磊,安琳,刘德泽   

  1. 071000 保定，河北大学附属医院肿瘤内科
  • 出版日期:2016-03-08 发布日期:2016-02-03
  • 通讯作者: 安琳，Email： 173745817@qq.com E-mail:173745817@qq.com

Research status of targeted drug and whole brain radiotherapy for nonsmall cell lung cancer with brain metastasis

Wang Xiaolei, An Lin, Liu Deze   

  1. Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China
  • Online:2016-03-08 Published:2016-02-03
  • Contact: An Lin, Email: 173745817@qq.com E-mail:173745817@qq.com

PDF

1430

被引次数

5

摘要： 全脑放疗延长了非小细胞肺癌脑转移患者的生存期，已成为其标准治疗方法。而分子靶向药物的出现是传统意义上的肿瘤治疗观念的一个重大革新，且具有服药方便，起效快，可同时改善颅内及颅外肿瘤病灶，不良反应轻，耐受性好等优点，为非小细胞肺癌脑转移的治疗提供了新的更优治疗方法。

关键词: 癌, 非小细胞肺, 肿瘤转移, 放射疗法, 靶向治疗

Abstract: Whole brain radiation therapy has become the standard treatment of nonsmall cell lung cancer (NSCLC) with brain metastasis, because it prolongs the survival times of NSCLC patients with brain metastases. The emergence of molecular targeted drugs is a major innovation in the traditional sense of the cancer treatment. Molecular targeted drugs have many advantages such as convenient dosing, rapid onset, improving the intracranial and extracranial tumor lesions at the same time, mild adverse reactions and good tolerance, which provide a new and better choice for the treatment of NSCLC patients with brain metastases.

Key words: Carcinoma, non-small-cell lung, Neoplasm metastasis, Radiotherapy, Targeted therapy